+/- Bupivacaine HCl
ApprovedSmall molecule
Pacira Pharmaceuticals, Inc+/- Bupivacaine HCl is one of 125 small molecule programs targeting Hemorrhoid. It is currently in Approved.
5
Indications
29
Total Trials
1
Active Trials
124
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1+/- Bupivacaine HCl
Pacira Pharmaceuticals, IncApproved
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xarelto
WWim Janssens
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
EXPAREL
Pacira Pharmaceuticals, IncPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postoperative Analgesia5 trials
Total Knee Arthroplasty4 trials
Liposomal Bupivacaine3 trials
Hemorrhoid2 trials
11 more indications
Inguinal hernia2 trials
Bupivacaine2 trials
Intraperitoneal Chemotherapy1 trial
Orthognathic Surgery1 trial
Bupivacaine Liposomal Injectable Suspension, Pain and Narcotic Use After Elective Orthognathic Surgery
Withdrawn·—·Phase 4·NCT03318757
Knee Replacement Surgery1 trial
Total Knee Replacement1 trial
Total Shoulder Arthroplasty1 trial
Hysterectomy1 trial
Spinal Fusion1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for +/- Bupivacaine HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company